Next Article in Journal
Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity
Next Article in Special Issue
Eriocitrin Inhibits Angiogenesis by Targeting VEGFR2-Mediated PI3K/AKT/mTOR Signaling Pathways
Previous Article in Journal
Nutritional Strategies to Prevent Weight Gain and Obesity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity

by
Ho Seon Lee
and
Chang-Ik Choi
*
Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Republic of Korea
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(19), 4181; https://doi.org/10.3390/nu15194181
Submission received: 23 August 2023 / Revised: 25 September 2023 / Accepted: 26 September 2023 / Published: 27 September 2023
(This article belongs to the Special Issue Functional Foods and Health Promotion)

Abstract

:
Lycium ruthenicum Murray (LRM; commonly known as black goji berry or black wolfberry), a plant in the Solanaceae family, grows in the deserts of China’s Qinghai–Tibet plateau. LRM is widely consumed in traditional Chinese medicine, and its fruits are frequently used as herbal remedies to treat heart disease, fatigue, inflammation, and other conditions. Many studies have reported that LRM is rich in functional phytochemicals, such as anthocyanins and polysaccharides, and has various pharmacological actions. This article reviews research on the biological and pharmacological effects of the constituents of LRM fruits. LRM has various pharmacological properties, such as antioxidant, anti-inflammatory, anti-radiation, immune-enhancing, anti-tumor, and protective effects. LRM has much promise as a dietary supplement for preventing many types of chronic metabolic disease.

Graphical Abstract

1. Introduction

For thousands of years, medicinal plants have been recognized as beneficial to human nutrition and health, and berries such as blueberry (Vaccinium spp.), raspberry (Rubus idaeus Linnaeus), cranberry (Vaccinium oxycoccos L.), bilberry (Vaccinium myrtillus L.), and goji berries (genus Lycium) are examples of such fruits [1]. Berries include numerous vitamins, minerals, and phytochemicals shown in in vivo and in vitro studies to promote health and protect against several chronic diseases [2].
Goji is a plant belonging to the Solanaceae family of the Lycium genus, and there are about ninety-seven species and six variants [3]. Besides the three medicinal species (Lycium barbarum L., L. chinense Miller, and L. ruthenicum Murray [LRM]) in China, goji berries have been discovered in America, Africa, Europe, and Asia [4]. Goji berries (wolfberries) are noted for red fruits as L. barbarum L. and L chinense Mill., which are mainly used in Chinese soups, herbal teas, tinctures, wines, and juices [5,6,7]; LRM, which is also used for medicinal purposes, is known as black goji berry (black wolfberry) and has a different composition [8]. According to Islam et al. [9], red goji berries have a larger quantity of carotenoids, while black goji berries have a higher content of phenol, tannin, and monomeric anthocyanin, and therefore have stronger antioxidant activity. Further, the fruit of LRM is high in phytochemicals such as flavonoids, anthocyanins, and polysaccharides, with antioxidant, anti-inflammatory, anti-radiation, immune-boosting, and anti-tumor properties [10]. These studies can contribute to the commercial food industry by providing an understanding of black goji berries.
We collected studies published in English primarily from PubMed, with secondary use of Google Scholar and Web of Science. To collect studies related to the origin, pharmacological activity, and uses of black goji berries, we used a combination of the following search terms: “black goji berries”, “black wolfberry”, “Lycium ruthenicum”, “pharmacological activity”, “antioxidant”, “anthocyanin”, and “polysaccharide”. We thoroughly evaluated and reviewed each paper’s research design, results, and comprehension.

2. Phytochemical Composition

A summary of the nutritional components of LRM is shown in Table 1. Carbohydrates were the most prevalent nutrient in LRM, followed by dietary fiber, and the remaining nutrients comprised protein, ash, and fat [11]. LRM is composed mostly of anthocyanins, proanthocyanidins, and carotenoids, as well as fatty acids, essential oils, coumarin and cinnamate derivatives, polysaccharides, alkaloids, and phenolic acids [12]. The majority of LRM research has concentrated on anthocyanins and polysaccharides, and Figure 1 shows the chemical structures of typical LRM components.

3. Pharmacological Properties

A summary of the pharmacological activities of LRM is described in Table 2.

3.1. Anti-Inflammatory Effects

Inflammation is a marker of numerous diseases and is associated with infection and the immune system, accompanied by the production of inflammatory mediators, the pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 [35]. Anti-inflammatory effects have been reported for LRM [13,14,15]. Lu et al. [16] evaluated the regulation of the expression of inflammation-related genes in response to LRM fruit extract treatment. Five-week-old male ApoE–/ – mice were randomly assigned into three groups with 10 mice per group. Each group was divided into a normal control (NC) group, Western diet (WD) group, and LRM extract-treated group. The NC group was fed a normal diet, and the other two groups were fed WD for 12 weeks. After administering WD for 8 weeks, 140 mg/kg of LRM extract or distilled water was additionally administered through oral gavages. When the LRM fruit extract-treated group was compared with the NC and WD groups, the expression of the pro-inflammatory gene Tnf-α was reduced, but Il-6 was not significantly changed. In contrast, the expression of the anti-inflammatory gene Il-4 was increased, while Il-10 maintained a similar level compared to the WD group. Thus, LRM supplementation reduced inflammation by controlling the expression of Tnf-α and Il-4.
The nuclear factor (NF)-κB pathway is a response to the pro-inflammatory cytokines TNF-α and IL-1, and plays an important role in the pathogenesis of chronic inflammatory diseases [36]. Chen et al. [17] reported that high and moderate doses of anthocyanin isolated from LRM fruits inhibited d-galactose (d-gal)-induced NF-κB activation and reduced the levels of inflammatory mediators such as cyclo-oxygenase-2, IL-1β, and TNF-α. Anthocyanins isolated from dried LRM fruits were extracted with ethanol.

3.2. Anti-Aging Effects

Aging, a growing global problem that has recently received much attention, meets the criteria of the International Classification of Diseases (ICD) [37]. Aging is a complex, time-dependent biological process accompanied by immunologic senescence, altered nutritional sensing, oxidative damage, mitochondrial failure, and other factors [38]. The composition of black goji berries alleviates these factors and contributes to anti-aging [13,14]. Xiong et al. [18] reported that a high dose of LRM fruit extract (10 mg/mL) significantly extended the average lifespan of C. elegans by 25.2%. In addition, in a thermal stress assay, the high-dose LRM extract significantly reduced the mortality rate of C. elegans by 34.0% compared to the control group (56.9%) (p < 0.05). The LRM fruit extract ensured high autonomous locomotivity in C. elegans. The proportion of motion A (with great mobility that can move independently and leave sinusoidal trails) nematodes in the control group decreased from 74% to 48% until the mid- to late stages of life (the 15th day), whereas it stayed above 90% in the group receiving large doses of LRM fruit extract. Meanwhile, the LRM fruit extract-treated group had a lower food intake than the control group, and the authors speculated that the goji berry extract could intervene in the calorie restriction pathway for life expectancy extension. Compared to the control group, the LRM-treated group alleviated the aging pigment accumulation, and the high-dose goji berry extract upregulated genes related to lifespan regulation, such as daf-16, sod-2, sod-3, hsp-16.2, sir-2.1, daf-12, and jnk-1. Mutations mu86 I, ok434 IV, and sy441 I in the daf-16, sir-2.1, and hsf-1 genes, respectively, reversed the lifespan extension provided by LRM fruit extract, confirming that these genes are required for goji berry-mediated increased longevity.

3.3. Anticancer Effects

The primary treatments for cancer include surgery, radiation therapy, and chemotherapy. However, these treatments are often associated with serious side effects, and a key challenge now is to find natural compounds with effective anticancer properties [39]. Here are some research reports on the anticancer properties of LRM [19,20]. Zhang et al. [21] extracted dried LRM fruits by water and ethanol precipitation to obtain crude polysaccharides. LRM polysaccharide 3S-1 (LRP3-S1) was then obtained by purifying it using anion exchange chromatography. Zhang et al. [21] evaluated the antiproliferative activity of the polysaccharide LRP3-S1 by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay using three pancreatic cancer cell lines: AsPC-1, BxPC-3, and PANC-1. Under treatment with LRP3-S1 for 72 h, proliferation decreased in a concentration-dependent manner, with values of 30.1%, 67.1%, and 29.0%, respectively, for each cell line. Conversely, LRP3-S1 showed an inhibitory ratio of about 10% in HPDE6-C7 and LO2 cells, indicating that LRP3-S1 may not show significant cytotoxicity in normal cell lines. In addition, a cell invasion assay showed that the cellular area in the lower chamber for BxPC-3 cells treated with LRP3-S1 was 92% and 57% at concentrations of 4.36 μM and 8.71 μM, respectively. This indicates that the invasive ability of BxPC-3 cells was attenuated by LRP3-S1 in a concentration-dependent manner. Moreover, p-AKT, p-GSK-3β, p-FAK, and p-p38 were downregulated in a concentration-gradient manner in BxPC-3 cells, suggesting that the FAK/AKT/GSK-3β signaling pathway and the p38 mitogen-activated protein kinase signaling pathway are involved in the regulation of cancer cell growth and invasion by LRP3-S1. Therefore, LRP3-S1-induced downregulation of these associated phosphorylated proteins could decrease pancreatic cancer cell proliferation and invasion ability.
Qin et al. [22] investigated synergistic anticarcinogenic effects and cell-cycle blockade in G0–G1 phase apoptosis (programmed cell death) via a reactive oxygen species (ROS)-dependent pathway under LRM-derived compound treatment. LRM crude polysaccharide was obtained by water extraction followed by ethanol precipitation, and LRM polysaccharide 4 (LRP4) was purified using an ion exchange column and gel permeation column. LRM anthocyanins were obtained through ethanol extraction. LRP4 and anthocyanins were concentrated by freeze-drying. The synergistic effect of LRP4 and anthocyanins (LRP4&AC), a mixture of 20 µg/mL LRM anthocyanin and various concentrations of LRP4 (150, 300, and 500 μg/mL), was measured. Based on MTT assay, LoVo cells (human colorectal carcinoma cells) were treated with LRP4&AC at concentrations of 150, 300, and 500 μg/mL for 24 h. This treatment reduced the viability of cancer cells to 87.2%, 83.5%, and 72.7%, respectively, in a concentration-dependent manner, and similar results were obtained after 48 h. In addition, lactate dehydrogenase (LDH) increased in a concentration-gradient manner, confirming that LRP4&AC has a cytotoxic effect by inducing cell-membrane lysis in tumor cells. The cytotoxicity of LRP4&AC was not specific to one type of carcinoma cells, since HepG2 cells (human hepatoma cells) displayed stunted development. In contrast, normal cells, RAW 264.7 cells (mouse macrophage cells), showed no significant reduction in cell viability. The antiproliferative effect of LRP4&AC on tumor cells consisted in cell-cycle arrest and induction of apoptosis. LRP4&AC inhibited the replication of LoVo cells by G0–G1 arrest. Cells at the S phase were reduced to 24.1% (150 μg/mL) and 17.8% (500 μg/mL), whereas cells at the G0–G1 phase were significantly increased to 66.2% and 73.9%, respectively. This suggested that LRP4&AC prevented cell progression at the G0–G1 phase, potentially by interfering with the initiation of DNA and histone synthesis. LRP4&AC induced tumor-cell apoptosis. The low dose (150 μg/mL) showed 18.2% of the early apoptotic stage and 16.5% of the late apoptotic stage, but the high dose increased these values to 20.9% and 22.4%, respectively. Additionally, LRP4&AC increased ROS levels in cancer cells in a dose-dependent manner. The low dose increased the ROS level by 19.9% and the high dose (500 μg/mL) by 24.2%. The redox balance of LoVo cells could be disturbed by increased oxidative stress due to ROS generated by LRPS&AC, which could cause apoptosis. The mechanism underlying the anticancer effects of LRP4&AC could involve the interaction of the PI3K/Akt and JAK2/STAT3 pathways, leading to an elevated Bax/Bcl-2 ratio, increased caspase-3 levels, and promotion of mitochondrial-mediated apoptosis.

3.4. Protective Effects

3.4.1. Hepatoprotective Effects

Chen et al. [13] showed the alleviating effect of LRM anthocyanin supplementation on d-gal-induced liver damage. LRM anthocyanins were obtained through ethanol extraction from dried LRM fruits, followed by concentration, purification, and freeze-drying. On histologic evaluation, the d-gal-treated group showed an increased unclear structure of hepatocytes and cell necrosis, but this visual evidence was improved by LRM anthocyanin treatment. In addition, intake of LRM anthocyanins reversed the results by reducing d-gal-induced serum AST and alanine transaminase (ALT) levels, and blood LDH concentrations. AST and ALT levels reflect the extent of liver damage, while LDH concentrations reflect the extent of cellular damage and inflammation. Moreover, Fas/FasL contributed to cell death receptor signaling, and LRM anthocyanin treatment alleviated d-gal-induced hepatocyte death by downregulating this mRNA level.
Lu et al. [16] investigated the beneficial impact of LRM fruit extract on the development of cholesterol-enriched, high-fat diet-induced nonalcoholic fatty liver disease (NAFLD). Serum aspartate transaminase (AST) levels were significantly increased in the WD group compared to the NC group, but levels were dramatically reduced in the WD group supplemented with LRM fruit extract. These results suggest that LRM fruit extract supplementation protects against liver injury. Additionally, although severe hepatic steatosis was evident in hematoxylin and eosin (H&E) and oil red O staining results for the WD group, LRM fruit extract significantly reduced the size of hepatic fat droplets in the WD group. Thus, LRM fruit extract supplementation had a protective function in cholesterol-induced NAFLD.

3.4.2. Neuroprotective Effects

A slow progressive loss of neurons leads to the progression of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease, and multiple system atrophy [40]. Brain-related aging, and the resulting oxidative stress, inflammatory responses, and apoptosis, are the most important causes of neurodegenerative diseases [41]. There are some reports of neuroprotective activity for black goji berries [14,23].
Chen et al. [17] reported a mechanism for LRM anthocyanin’s potential neuroprotective effect in d-gal-treated rats. LRM anthocyanins were obtained through ethanol extraction from dried LRM fruits, followed by concentration and purification. Female Sprague Dawley rats (12 weeks old, average weight 200–40 g) were divided into five groups of 11 rats each: a control group given normal saline; a d-gal group (100 mg/kg); and three LRM anthocyanin groups by concentration (100 mg/kg of d-gal + 50, 100, or 200 mg/kg of LRM anthocyanins). In the Morris water maze test, the d-gal group had impaired spatial learning and memory, but the LRM anthocyanin groups recovered from these memory impairments. On a day-5 swimming-path test, the control group found the best platform, but the d-gal group found a platform without a specific direction, and the LRM anthocyanins groups performed better than the d-gal group in platform finding. Notably, performance in the high-dose LRM anthocyanin group was comparable to that in the control group. The probe test was performed on day 6, and high- and medium-dose LRM anthocyanins significantly reduced latency to the platform in the d-gal group. Compared to the d-gal group, the LRM anthocyanin groups had a dramatically enhanced number of crossings and time spent in the target quadrant, indicating that LRM anthocyanins may lessen the memory impairment caused by d-gal. In step-down-type passive avoidance tests, the number of errors in the d-gal group was significantly greater than in the control group; medium- (p < 0.05) and high-dose (p < 0.01) LRM anthocyanins significantly reduced the number of errors. The d-gal group also showed a significant reduction in step-down latency (p < 0.001), but medium- and high-dose LRM anthocyanins markedly prolonged step-down latency (p < 0.01). These findings suggest that LRM anthocyanins improved memory function and passive avoidance behavior in the d-gal group. The d-gal-treated model causes brain senescence and can lead to animals developing symptoms similar to Alzheimer’s disease. Intracorporeal free amines and d-gal can combine to produce advanced glycation end products (AGEs), and AGEs and their receptors (RAGEs) can increase ROS and inflammatory factors, and eventually impair cognitive performance. Western blot results showed that RAGE expression increased significantly in the d-gal versus the control group, whereas RAGE expression was significantly reduced by LRM anthocyanins. Moreover, various brain insults stimulate microglia/astrocytes, which are components of the neurovascular unit, and neuroinflammation is greatly influenced by the interaction between these two cell types [42]. Ionized calcium-binding adaptor molecule-1 and glial fibrillary acidic protein are markers indicating active microglia and astrocytes, respectively. Western blot results showed that these two markers were elevated in the d-gal group but were significantly suppressed by LRM anthocyanins (p < 0.05).
Hu et al. [24] evaluated the neuroprotective activity of polyphenolic glycosides compounds 1 (lyciumserin A), 2 (lyciumserin B), 3 (lyciumserin C), 5/6 (lyciumserin E and F), 11 (puchikrin), 16 (6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranosyl-methanol), and 17/18 (6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyranoside and 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranoside) isolated from LRM extracts. Lyciumserin A, B, C, E, and F are newly named compounds first isolated by Hu et al. [24] Figure 2 shows the chemical structures of these compounds. In PC12 cells, the neurotoxin 6-hydroxydopamine hydrobromide (6-OHDA) reduced cell viability to 51.9% compared to the control group. In contrast, when treated with compounds 13 and 5/6 (50 and 100 μM), cell viability was restored to almost 70%, confirming that the neurotoxic effect of 6-OHDA was delayed. Notably, 100 μM of compound 2 showed the highest neuroprotective effect (72.4%), which was higher than that for rasagiline, a positive control group (70.5%). Based on this protective effect, the changes in PC12 cell morphology were evaluated. Pre-treatment with compounds 1 (50 μM) and 2 (100 μM) considerably improved morphologic alterations compared to cells treated with 6-OHDA alone, which caused evident cell shrinkage and poor adherence. In addition, neuroprotective effects for selected compounds were demonstrated by staining cells with fluorescein diacetate (FDA) and propidium iodide (PI). FDA stains viable cells, whereas PI stains damaged cells. Compounds 1 and 2 increased FDA-stained cells and decreased PI-stained cells. These findings imply that compounds 1 and 2 can prevent 6-OHDA-induced apoptosis in PC12 cells. Meanwhile, compounds 1, 2, 11, 16, and 17/18, which are some of the phenolic glycosides in LRM, exhibited monoamine oxidase B (MAO-B) inhibition of more than 50% at a concentration of 100 μM. The 50% inhibitory concentration (IC50) values for each compound were 60.7 ± 1.7 μM (compound 1), 22.2 ± 0.8 μM (compound 2), 79.3 ± 2.4 μM (compound 11), 68.9 ± 1.5 μM (compound 16), and 75.5 ± 3.8 μM (compound 17/18). MAO-B inhibitors can reduce neurotoxin formation by preventing dopamine oxidation, and by reducing free-radical formation due to monoamine oxidation. MAO-B inhibitors continue to be developed for the treatment of Parkinson’s disease [43,44]. Notably, compound 2 has both MAO-B inhibitory activity and neuroprotective activity, and the authors reasoned that this is because compound 2 is the only structure with a p-coumaric acid moiety, and a glucose moiety located at C-4‴’ (Figure 2B).

3.4.3. Cardioprotective Effects

Cardioprotection refers to the ability of cardiac muscle to endure injuries such as metabolic stress or ischemia-reperfusion [45]. Yossa Nzeuwa et al. [25] showed that an aqueous extract of dried fruits of black goji berry was effective against isoproterenol-induced acute myocardial ischemia. A total of forty Institute of Cancer Research (ICR) mice were randomly assigned to five groups of eight mice each. Group I (the normal group) and Group II (the negative control group) mice received 1.0 mL of 0.5% saline intragastrically each day. For 8 days, groups III and IV received LRM fruit extract suspension (375 mg/kg or 750 mg/kg), and group V received propranolol (positive control group; 15 mg/kg) through intragastric intubation. The mice in Groups II, III, IV, and V received two isoproterenol (20 mg/kg) intraperitoneal injections repeated 24 h apart on days 7 and 8. Creatine kinase-myocardial band (CK-MB) and LDH are myocardial marker enzymes present in cardiac muscle cells; they escape into the blood when myocardial necrosis occurs [46]. In the isoproterenol-alone group (Group II), the levels of both enzymes were significantly increased (p < 0.001) compared to the control group (Group I); however, pretreatment with high-dose LRM fruit extract (750 mg/kg; Group IV) led to significantly reduced levels of both enzymes (p < 0.05). These results were consistent with previous studies, in which LRM fruit extract protected against cardiac injury induced by overexertion in rats [47]. In addition, histopathologic examination showed that low-dose (Group III) and high-dose LRM fruit extract (Group IV) were associated with reduced myocardial tissue damage compared to the isoproterenol-alone group (Group II). Thus, in myocardial tissue treated with LRM fruit extract, inflammatory cell infiltration, and traces or signs of cellular edema and necrosis were reduced or returned to normal.

3.4.4. Protection against Radiation Injury

Ionizing radiation particles pose a major threat to human health because of their physical ability to generate free radicals that cause direct and indirect DNA damage [48]. Amifostine (WR-2721) is the only cytoprotective agent approved by the US Food and Drug Administration as prophylaxis to protect against radiation injury; however, widespread use of amifostine is limited due to side effects such as hypotension, vomiting, and nausea [49,50]. Duan et al. [26] evaluated the radioprotective effect of LRM fruit extract. A total of 180 Kunming mice were randomly assigned in groups of 60 according to irradiation (days 3, 7, and 14). Each group was designated as a control group, model group, positive drug group (amifostine 150 mg/kg), or LRM fruit extract-treated group (2, 4, or 8 g/kg). All mice, except those in the control group, were exposed to 5 Gy of X-ray radiation at one time distributed equally across the entire body. On day 3, 7, and 14 following irradiation, measurements of body weight, hemogram, thymus index, spleen index, DNA, caspase-3, caspase-6, and P53 were carried out. LRM fruit extract showed a preventive effect against weight loss in irradiated mice but did not show significant results on the hemogram (leukocytes, erythrocytes, hemoglobin, and thrombocytes). The thymus index increased significantly (p < 0.05) in the LRM fruit extract middle- and high-dose groups on day 3 and 7 after irradiation. In addition, the spleen index increased significantly (p < 0.05) in the low- and middle-dose groups on day 14, compared to the model group. Further, the DNA content increased significantly (p < 0.05) with all LRM fruit extract doses on day 3, and with the low and middle LRM fruit extract doses on day 7 and 14, compared to the model group. Moreover, the low- and middle-dose LRM fruit extract-treated groups showed significantly decreased levels of caspase-6 on day 7 after irradiation (p < 0.05), and significantly decreased levels of caspase-3 on day 14 after irradiation (p < 0.05), compared to the model group. The caspase results supported the P53 data, and immunohistochemical images showed that P53 expression was decreased in the LRM fruit extract-treated group.

3.5. Immunomodulatory Effects

Nitric oxide (NO), a signaling molecule that can modulate immunity, is mainly produced by macrophages [51]. The NO generated changes the phenotype of macrophages from M2 to M1 [52]. While the M1 phenotype suppresses tumors by phagocytosis, the M2 phenotype subdues the activated immune response, helping tumor progression [53]. Lipopolysaccharides (LPS) are agents that stimulate macrophage NO production, but their clinical application is limited due to side effects and dose-limiting toxicity [52]. Peng et al. [27] assessed the immunomodulatory activity by measuring NO production by LRM polysaccharide pectin-5 (LRPP5) in RAW264.7 macrophages. LRPP5 was obtained from crude polysaccharides extracted (ethanol precipitation after water extraction) from LRM fruit powder and purified by ion exchange and gel permeation chromatography. An MTT assay was performed to observe the effect of LRPP5 (50, 100, 200, 500, and 1000 μg/mL) on cell viability in RAW264.7 cells treated for 24 h. Cell viability was dramatically enhanced at LRPP5 concentrations of 500 and 1000 μg/mL; with the highest concentration, cell viability was enhanced approximately 3.1-fold compared to the control group. At lower LRPP5 concentrations, there was no apparent effect. An LRPP5 concentration of ≤200 μg/mL, with no appreciable change in cell viability, was selected for NO estimation. NO produced by macrophages is converted to nitrite ions, which indicate macrophage activation. LRPP5 treatment (25, 50, 100, and 200 μg/mL) for 24 h significantly increased NO production compared to the control group (p < 0.01), suggesting that LRPP5 stimulated macrophages to release NO.
In cyclophosphamide (Cy)-induced immunosuppression in mice, LRM polysaccharide 3 (LRP3) was reported to have immunomodulatory benefits [28]. LRM crude polysaccharide was isolated using dried LRM fruit powder through water extraction and ethanol precipitation. Purified LRP3 was obtained from LRM crude polysaccharide using ion exchange and gel permeation chromatography. Female Kunming mice were randomly divided into five groups (10 mice per group): a control group, a Cy group, and LRP3-treated groups (25, 50, and 100 mg/kg of LRP3) that received an intraperitoneal injection with saline or LRP3 once a day for 10 consecutive days. The spleen and thymus indices in the Cy group were significantly lower than those in the control group (p < 0.05), clearly indicating a decreased immunologic response. However, both parameters significantly improved in all LRP3-treated groups compared to the Cy group (p < 0.05). These results, showing that LRP3 is involved in the recovery of the spleen and thymus indices in mice, agree with previous findings [26]. In addition, an MTT assay was performed to evaluate the effect of LRP3 on the proliferation of spleen cells. Splenocytes from each group were cultured for 24 h and 5.0 µg/mL of lectin (T cell stimulation) and LPS (B cell stimulation) were added. After 72 h, the proliferative effect on stimulated lymphocytes was confirmed. Under the lectin-treated condition, it was confirmed that proliferation in the LRP3-treated group (25, 50, and 100 mg/kg) was significantly increased (p < 0.05) by 55%, 64%, and 76%, respectively, compared to the Cy group. Similarly, under the LPS treatment condition, the LRP3-treated group showed significant increases (p < 0.05) in spleen-cell proliferation by 65%, 74%, and 87%, respectively, in a gradient manner compared to the Cy group. Further, the reduced index caused by Cy in the evaluation of macrophage phagocytic function was significantly reversed (p < 0.05), in a concentration-dependent manner, by LRP3 pretreatment. Moreover, LRP3 pretreatment demonstrated a regulatory humoral immune-enhancing function by dose-dependently improving (p < 0.05) the reduced value produced by Cy in the serum hemolysis production test. Meanwhile, pretreatment with LRM in mice with Cy-induced immunosuppression significantly elevated (p < 0.05) the levels of IL-2, IL-6, and TNF-α.
Recently, Xu et al. [29] reported that LRM anthocyanins inhibited the hyperproliferation and aggressive invasion of synovial fibroblasts (SF) in patients with rheumatoid arthritis (RA), thus suggesting the potential for LRM anthocyanins in the treatment of RA. LRM anthocyanins were obtained commercially and purified directly. LRM anthocyanins (100, 200, and 400 μg/mL) significantly decreased (p < 0.01) cell viability in a concentration-dependent manner at both 24 and 48 h in an MTT assay. Comparable results were found with the conventional chemotherapeutic drug methotrexate (MTX) 400 g/mL. The findings for LRM anthocyanins from the MTT assay were consistent with results from a Cell Counting Kit-8 assay. In a calcein-acetyl methoxy methyl ester/propidium iodide assay, LRM anthocyanins also inhibited SF proliferation similarly to MTX. Notably, immunosuppressive reactions, a major side effect of MTX, were not observed with LRM anthocyanins. Unlike MTX, LRM anthocyanins 400 g/mL had no effect on T cells and monocyte/macrophage development.

3.6. Other Effects

3.6.1. Anti-Fatigue Activity

Control of fatigue is crucial because such control can prevent the development of many serious health problems; indeed, fatigue is regarded as an intermediate condition between health and sickness [54]. Bi et al. [15] reported that LRM fruit water extract has anti-fatigue activity. A total of 80 Kunming mice (sex ratio 1:1) were orally administered with distilled water (control group) or LRM fruit extract (0.05, 0.1, 0.2, or 0.5 mg/g water extract) once a day for 28 days. There was no significant difference in body weight between the control and treatment groups; however, swimming duration increased in a dose-dependent manner compared to the control group. Significant results were observed at all concentrations, with the greatest time increase at the highest dose (p < 0.05, p < 0.01, p < 0.001, and p < 0.001 for LRM fruit water extract 0.05, 0.1, 0.2, or 0.5 mg/g, respectively). This suggests that the LRM fruit water extract significantly alleviated exercise-induced fatigue. As described above, LRM had an anti-fatigue effect through the reduction of inflammation and oxidative stress, and an increase in SOD was observed along with decreases in LDH, TNF-α, IL-6, IL-1β, and IL-2.
Ni et al. [30] reported the anti-fatigue activity of polysaccharides in black goji berries. Eight-week-old male BALB/c mice were assigned to five groups (6 mice per group): an intact group (control), p.s. group (as a model group; saline treatment with a swimming test), and LRM polysaccharide-treated groups (50, 100, and 200 mg/kg). Saline was administered to the non-LRM groups, and only the intact group was spared the swimming test. The polysaccharide fraction of hot water-extracted LRM or saline was orally administered to mice once daily for 15 days. In the swimming test, immobility times were significantly reduced (p < 0.05) for LRM polysaccharide 50 and 200 mg/kg. Immobility times indicate the degree of fatigue, and their decrease means anti-fatigue activity. For serum biochemical parameters measured after the swimming test, the markers reduced by the forced swim test were restored to normal by LRM polysaccharide. Increases in serum blood urea nitrogen (BUN), creatine phosphokinase (CPK), LDH, and malondialdehyde (MDA) were observed with the progress of the swim test but returned to normal with LRM polysaccharide 100 mg/kg and 200 mg/kg. Conversely, glucose, superoxide dismutase (SOD), and glutathione peroxidase (GPx) levels reduced by the swim test were increased again with LRM polysaccharide administration.

3.6.2. Anti-Obesity and Antidiabetic Activity

Obesity is caused by an imbalance between dietary energy intake and expenditure [55]. It is an important health problem worldwide because it is associated with metabolic conditions such as type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease [56]. Obesity is usually managed with diet, physical activity and pharmaceuticals [57]. However, some pharmaceuticals may have serious side effects; thus, there is an increased need for natural products considered relatively safe [58,59]. There is a report related to the anti-obesity effect of LRM extract [16].
Pancreatic lipase is a digestive enzyme that breaks down fat and improves triglyceride (TG) absorption; therefore, blocking pancreatic lipase can have an anti-obesity effect [60]. Cholesterol esterase (CEase) is also a lipolytic enzyme and is involved in the absorption of dietary cholesterol [61]. Zhao et al. [31] reported that LRM seed oil had inhibitory activity against both pancreatic lipase and CEase. For pancreatic lipase, the inhibitory activity of LRM seed oil increased in a concentration-dependent manner, and the IC50 value was reported as 12.4 ± 0.1 mg/mL. In addition, the inhibitory activity of LRM seed oil against CEase was enhanced in a gradient manner, and the IC50 value was 2.6 ± 0.1 mg/mL, indicating a very strong effect. The inhibitory pattern of p-nitrophenyl butyrate, a substrate of CEase, was reversible, and non-competitive inhibition was determined using a Lineweaver–Burk double reciprocal plot.
In another study by Zhao et al. [32], bioactive phenylpropanoid derivatives isolated from LRM were investigated for potential antidiabetic activity due to α-glucosidase inhibitory activity. Although most compounds showed weak activity, compound 13 (ethyl p-trans-coumarate isolated from LRM) was superior and had similar effects to the positive control (acarbose).

3.6.3. Activity against Influenza

Viral infections can lead to global problems and, annually, influenza poses a health risk to millions of people worldwide by producing severe respiratory infections [62]. Kurskaya et al. [33] noted the antiviral activity of an LRM fruit extract against influenza A/Novosibirsk/RII-27192S/2020 (H3N2) virus. In an MTT assay using Madin–Darby canine kidney (MDCK) cells, the 50% cytotoxicity concentration (CC50) was more than 125 μg/mL, so a concentration range of 15.6–500 μg/mL was used in the experiment. Anti-influenza activity was considered effective when inhibition of A/H3N2 virus-infected MDCK cells of 50% or more was exhibited. The MTT assay results showed that the LRM fruit extract (15.6–125 μg/mL) enhanced the viability of A/H3N2 virus-infected MDCK cells in a concentration-dependent manner compared to the control group.

3.6.4. Tyrosinase Inhibitory Activity

Tyrosinase inhibitory activity reduces skin pigmentation and leads to skin whitening; however, kojic acid, a conventional inhibitor, is cytotoxic. Therefore, natural products with relatively few side effects are attracting attention as possible therapeutic candidates with a tyrosinase inhibitory function. According to the study by Shen et al. [34], dried LRM fruit powder was dissolved in hydrochloric acid aqueous solution and used as LRM extract. In addition, the LRM extract was eluted with a resin column and purified LRM anthocyanins was obtained through freeze-drying. LRM anthocyanins inhibited tyrosinase monophenolase: purified anthocyanin (IC50 1.5 ± 0.06 mg/mL) was superior to LRM extract (IC50 3.0 ± 0.02 mg/mL) but weaker than kojic acid (IC50 3.0 ± 0.02 µg/mL). LRM anthocyanins bound reversibly and competitively to tyrosinase monophenolase when the mechanism was investigated (enzyme inhibition constant; Ki 39.8 ± 1.4 mg/mL). The inhibitory activity against diphenolase was also measured, and purified anthocyanin (3 mg/mL, 42.2 ± 0.77%) had a greater inhibitory power than the LRM extract (3 mg/mL, 30.8 ± 1.0%); the inhibitory activity was reversible and non-competitive (enzyme–substrate complex; Kis 2.4 ± 0.10 mg/mL). The IC50 for kojic acid was 1.90 ± 0.05 µg/mL.

3.6.5. Antioxidant Effects

Antioxidants play a crucial role in preventing oxidative cell damage, which can result in problems such as Alzheimer’s disease, cancer, cardiovascular disease, and chronic inflammation [63]. Anthocyanins, polyphenols from the flavonoid family, are found in practically all fruits and vegetables and provide these foods with their anti-inflammatory and antioxidant capabilities [64]. There have been numerous reports on the antioxidant activity of LRM over the past few years. The antioxidant properties of LRM have been demonstrated through various methods including DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay [14,16,31,32,34,65,66,67,68], ABTS (2,2′-azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid) radical scavenging assay [14,31,34,66], hydroxyl radical scavenging assay [34,65,67], SOD radical scavenging assay [13,15,18,23,25,30,34,65,67], lipid peroxidation assay [13,14,16,17,25,30,69], antioxidant enzyme activity assay [13,14,16,17,18,23,25,30,69], ROS measurement [14,16,17,23,69,70], oxygen radical absorbance capacity assay [19,32], peroxyl radical scavenging capacity assay [19], and cellular antioxidant activity assay [19].

4. Conclusions

LRM has various pharmacological properties, including antioxidant, anti-inflammatory, anti-aging, anticancer, immunomodulatory, anti-fatigue, anti-obesity, antidiabetic, antiviral, and tyrosinase inhibitory activity. LRM also has protective effects, such as hepatoprotection, neuroprotection, cardioprotection, and radioprotection. Most of these properties are aligned with the roles of polyphenols, flavonoids, anthocyanins, and functional polysaccharides in LRM, and there are many relevant findings. Black goji berry has the potential to contribute to the development of food additives and functional foods as well as the treatment of diseases based on various pharmacological activities and can also be applied in medicine and cosmetics. Clinical research results have been reported for L. barbarum and L. chinense, well-known as goji berries, but not for LRM. The results are insufficient to confirm safety and efficacy for LRM in humans because most LRM studies are still carried out at the cellular and animal level; therefore, additional clinical research is required. The results discussed in our review paper demonstrate that LRM has the potential to be used in the treatment of a variety of diseases and could also serve as a steppingstone for future clinical research.

Author Contributions

Conceptualization, H.S.L. and C.-I.C.; formal analysis, H.S.L.; investigation, H.S.L.; project administration, C.-I.C.; resources, C.-I.C.; supervision, C.-I.C.; writing—original draft preparation, H.S.L.; writing—review and editing, C.-I.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing is not applicable to this article.

Acknowledgments

This research was supported by the Integrated Research Institute for Drug Development (IRIDD), College of Pharmacy, Dongguk University-Seoul, Republic of Korea.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

6-OHDA6-Hydroxydopamine hydrobromide
ABTS 2,2′-Azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid
AGEsAdvanced glycation end products
ALTAlanine transaminase
ASTAspartate transaminase
BUNBlood urea nitrogen
CC5050% Cytotoxicity concentration
CEaseCholesterol esterase
CK-MBCreatine kinase-myocardial band
CPKCreatine phosphokinase
CyCyclophosphamide
d-gald-galactose
DPPH 2,2-Diphenyl-1-picrylhydrazyl
FDAFluorescein diacetate
GPxGlutathione peroxidase
H&EHematoxylin and eosin
H3N2Influenza A/Novosibirsk/RII-27192S/2020
IC5050% Inhibitory concentration
ICDInternational Classification of Diseases
ICRInstitute of Cancer Research
ILInterleukin
LDHLactate dehydrogenase
LPSLipopolysaccharides
LRP3LRM polysaccharide 3
LRPP5LRM polysaccharide pectin-5
LRMLycium ruthenicum Murray
LRP3-S1LRM polysaccharide 3-S1
LRP4&ACLRM polysaccharide 4 and anthocyanin
MAO-BMonoamine oxidase B
MDAMalondialdehyde
MDCKMadin-Darby canine kidney
MTT3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
MTXMethotrexate
NAFLDNonalcoholic fatty liver disease
NC Normal control
NF-κB Nuclear factor-κB
NONitric oxide
PIPropidium iodide
RARheumatoid arthritis
RAGEsAGEs and their receptors
ROSReactive oxygen species
SFSynovial fibroblasts
SODSuperoxide dismutase
TGTriglyceride
TNF-αTumor necrosis factor-α
WDWestern diet

References

  1. Salo, H.M.; Nguyen, N.; Alakärppä, E.; Klavins, L.; Hykkerud, A.L.; Karppinen, K.; Jaakola, L.; Klavins, M.; Häggman, H. Authentication of Berries and Berry-Based Food Products. Compr. Rev. Food Sci. Food Saf. 2021, 20, 5197–5225. [Google Scholar] [CrossRef]
  2. Golovinskaia, O.; Wang, C.-K. Review of Functional and Pharmacological Activities of Berries. Molecules 2021, 26, 3904. [Google Scholar] [CrossRef]
  3. Yao, R.; Heinrich, M.; Weckerle, C.S. The Genus Lycium as Food and Medicine: A Botanical, Ethnobotanical and Historical Review. J. Ethnopharmacol. 2018, 212, 50–66. [Google Scholar] [CrossRef] [PubMed]
  4. da Miguel, M.G. Chemical and Biological Properties of Three Poorly Studied Species of Lycium Genus—Short Review. Metabolites 2022, 12, 1265. [Google Scholar] [CrossRef] [PubMed]
  5. Potterat, O. Goji (Lycium barbarum and L. Chinense): Phytochemistry, Pharmacology and Safety in the Perspective of Traditional Uses and Recent Popularity. Planta Med. 2010, 76, 7–19. [Google Scholar] [CrossRef] [PubMed]
  6. Cheng, J.; Zhou, Z.-W.; Sheng, H.-P.; He, L.-J.; Fan, X.-W.; He, Z.-X.; Sun, T.; Zhang, X.; Zhao, R.J.; Gu, L.; et al. An Evidence-Based Update on the Pharmacological Activities and Possible Molecular Targets of Lycium Barbarum Polysaccharides. Drug Des. Devel. Ther. 2015, 9, 33–78. [Google Scholar]
  7. Ma, Z.F.; Zhang, H.; Teh, S.S.; Wang, C.W.; Zhang, Y.; Hayford, F.; Wang, L.; Ma, T.; Dong, Z.; Zhang, Y.; et al. Goji Berries as a Potential Natural Antioxidant Medicine: An Insight into Their Molecular Mechanisms of Action. Oxid. Med. Cell. Longev. 2019, 2019, e2437397. [Google Scholar] [CrossRef]
  8. Peng, Q.; Lv, X.; Xu, Q.; Li, Y.; Huang, L.; Du, Y. Isolation and Structural Characterization of the Polysaccharide LRGP1 from Lycium Ruthenicum. Carbohydr. Polym. 2012, 90, 95–101. [Google Scholar] [CrossRef]
  9. Islam, T.; Yu, X.; Badwal, T.S.; Xu, B. Comparative Studies on Phenolic Profiles, Antioxidant Capacities and Carotenoid Contents of Red Goji Berry (Lycium barbarum) and Black Goji Berry (Lycium ruthenicum). Chem. Cent. J. 2017, 11, 59. [Google Scholar] [CrossRef]
  10. Wang, H.; Li, J.; Tao, W.; Zhang, X.; Gao, X.; Yong, J.; Zhao, J.; Zhang, L.; Li, Y.; Duan, J. Lycium Ruthenicum Studies: Molecular Biology, Phytochemistry and Pharmacology. Food Chem. 2018, 240, 759–766. [Google Scholar] [CrossRef]
  11. Liu, Z.; Liu, B.; Wen, H.; Tao, Y.; Shao, Y. Phytochemical Profiles, Nutritional Constituents and Antioxidant Activity of Black Wolfberry (Lycium ruthenicum Murr.). Ind. Crops Prod. 2020, 154, 112692. [Google Scholar] [CrossRef]
  12. Sharma, R.; Raghuvanshi, R.; Kumar, R.; Thakur, M.S.; Kumar, S.; Patel, M.K.; Chaurasia, O.P.; Saxena, S. Current Findings and Future Prospective of High-Value Trans Himalayan Medicinal Plant Lycium Ruthenicum Murr: A Systematic Review. Clin. Phytoscience 2022, 8, 3. [Google Scholar] [CrossRef]
  13. Chen, S.; Wang, H.; Hu, N. Long-Term Dietary Lycium Ruthenicum Murr. Anthocyanins Intake Alleviated Oxidative Stress-Mediated Aging-Related Liver Injury and Abnormal Amino Acid Metabolism. Foods 2022, 11, 3377. [Google Scholar] [CrossRef] [PubMed]
  14. Chen, S.; Hu, N.; Wang, H.; Wu, Y.; Li, G. Bioactivity-Guided Isolation of the Major Anthocyanin from Lycium Ruthenicum Murr. Fruit and Its Antioxidant Activity and Neuroprotective Effects in Vitro and in Vivo. Food Funct. 2022, 13, 3247–3257. [Google Scholar] [CrossRef]
  15. Bi, Y.; Liu, X.; Liu, Y.; Wang, M.; Shan, Y.; Yin, Y.; Meng, X.; Sun, F.; Li, H.; Li, Z. Molecular and Biochemical Investigations of the Anti-Fatigue Effects of Tea Polyphenols and Fruit Extracts of Lycium Ruthenicum Murr. on Mice with Exercise-Induced Fatigue. Front. Mol. Biosci. 2023, 10, 1223411. [Google Scholar] [CrossRef]
  16. Lu, K.; Wang, J.; Yu, Y.; Wu, Y.; He, Z. Lycium Ruthenicum Murr. Alleviates Nonalcoholic Fatty Liver in Mice. Food Sci. Nutr. 2020, 8, 2588–2597. [Google Scholar] [CrossRef]
  17. Chen, S.; Zhou, H.; Zhang, G.; Meng, J.; Deng, K.; Zhou, W.; Wang, H.; Wang, Z.; Hu, N.; Suo, Y. Anthocyanins from Lycium Ruthenicum Murr. Ameliorated d-Galactose-Induced Memory Impairment, Oxidative Stress, and Neuroinflammation in Adult Rats. J. Agric. Food Chem. 2019, 67, 3140–3149. [Google Scholar] [CrossRef]
  18. Xiong, L.; Deng, N.; Zheng, B.; Li, T.; Liu, R.H. HSF-1 and SIR-2.1 Linked Insulin-like Signaling Is Involved in Goji Berry (Lycium Spp.) Extracts Promoting Lifespan Extension of Caenorhabditis Elegans. Food Funct. 2021, 12, 7851–7866. [Google Scholar] [CrossRef]
  19. Xiong, L.; Deng, N.; Zheng, B.; Li, T.; Liu, R.H. Goji Berry (Lycium spp.) Extracts Exhibit Antiproliferative Activity via Modulating Cell Cycle Arrest, Cell Apoptosis, and the P53 Signaling Pathway. Food Funct. 2021, 12, 6513–6525. [Google Scholar] [CrossRef]
  20. He, F.; Zhang, S.; Li, Y.; Chen, X.; Du, Z.; Shao, C.; Ding, K. The Structure Elucidation of Novel Arabinogalactan LRP1-S2 against Pancreatic Cancer Cells Growth in Vitro and in Vivo. Carbohydr. Polym. 2021, 267, 118172. [Google Scholar] [CrossRef]
  21. Zhang, S.; He, F.; Chen, X.; Ding, K. Isolation and Structural Characterization of a Pectin from Lycium Ruthenicum Murr and Its Anti-Pancreatic Ductal Adenocarcinoma Cell Activity. Carbohydr. Polym. 2019, 223, 115104. [Google Scholar] [CrossRef] [PubMed]
  22. Qin, X.; Wang, X.; Xu, K.; Yang, X.; Wang, Q.; Liu, C.; Wang, X.; Guo, X.; Sun, J.; Li, L.; et al. Synergistic Antitumor Effects of Polysaccharides and Anthocyanins from Lycium Ruthenicum Murr. on Human Colorectal Carcinoma LoVo Cells and the Molecular Mechanism. Food Sci. Nutr. 2022, 10, 2956–2968. [Google Scholar] [CrossRef] [PubMed]
  23. Deng, K.; Li, Y.; Xiao, M.; Wang, F.; Zhou, P.; Zhang, W.; Heep, A.; Li, X. Lycium Ruthenicum Murr Polysaccharide Protects Cortical Neurons against Oxygen-Glucose Deprivation/Reperfusion in Neonatal Hypoxic-Ischemic Encephalopathy. Int. J. Biol. Macromol. 2020, 158, 562–568. [Google Scholar] [CrossRef] [PubMed]
  24. Hu, Y.-K.; Bai, X.-L.; Yuan, H.; Zhang, Y.; Ayeni, E.A.; Liao, X. Polyphenolic Glycosides from the Fruits Extract of Lycium Ruthenicum Murr and Their Monoamine Oxidase B Inhibitory and Neuroprotective Activities. J. Agric. Food Chem. 2022, 70, 7968–7980. [Google Scholar] [CrossRef]
  25. Yossa Nzeuwa, I.B.; Xia, H.; Shi, Y.; Yang, C.; Shah, M.W.; Guo, B.; Wang, L.; Sun, G. Fatty Acid and Mineral Contents of Lycium Ruthenicum Murr. and Antioxidant Activity against Isoproterenol-Induced Acute Myocardial Ischemia in Mice. Food Sci. Nutr. 2020, 8, 1075–1081. [Google Scholar] [CrossRef]
  26. Duan, Y.; Chen, F.; Yao, X.; Zhu, J.; Wang, C.; Zhang, J.; Li, X. Protective Effect of Lycium Ruthenicum Murr. Against Radiation Injury in Mice. Int. J. Environ. Res. Public Health 2015, 12, 8332–8347. [Google Scholar] [CrossRef]
  27. Peng, Q.; Xu, Q.; Yin, H.; Huang, L.; Du, Y. Characterization of an Immunologically Active Pectin from the Fruits of Lycium Ruthenicum. Int. J. Biol. Macromol. 2014, 64, 69–75. [Google Scholar] [CrossRef]
  28. Gong, Y.; Wu, J.; Li, S.-T. Immuno-Enhancement Effects of Lycium Ruthenicum Murr. Polysaccharide on Cyclophosphamide-Induced Immunosuppression in Mice. Int. J. Clin. Exp. Med. 2015, 8, 20631–20637. [Google Scholar]
  29. Xu, K.; Qin, X.; Zhang, Y.; Yang, M.; Zheng, H.; Li, Y.; Yang, X.; Xu, Q.; Li, Y.; Xu, P.; et al. Lycium Ruthenicum Murr. Anthocyanins Inhibit Hyperproliferation of Synovial Fibroblasts from Rheumatoid Patients and the Mechanism Study Powered by Network Pharmacology. Phytomedicine 2023, 118, 154949. [Google Scholar] [CrossRef]
  30. Ni, W.; Gao, T.; Wang, H.; Du, Y.; Li, J.; Li, C.; Wei, L.; Bi, H. Anti-Fatigue Activity of Polysaccharides from the Fruits of Four Tibetan Plateau Indigenous Medicinal Plants. J. Ethnopharmacol. 2013, 150, 529–535. [Google Scholar] [CrossRef]
  31. Zhao, X.; Dong, B.; Li, P.; Wei, W.; Dang, J.; Liu, Z.; Tao, Y.; Han, H.; Shao, Y.; Yue, H. Fatty Acid and Phytosterol Composition, and Biological Activities of Lycium Ruthenicum Murr. Seed Oil. J. Food Sci. 2018, 83, 2448–2456. [Google Scholar] [CrossRef] [PubMed]
  32. Zhao, S.-S.; Li, S.; Luo, Z.-H.; Zhou, Z.-Q.; Li, N.; Wang, Y.; Yao, X.-S.; Gao, H. Bioactive Phenylpropanoid Derivatives from the Fruits of Lycium Ruthenicum Murr. Bioorganic Chem. 2021, 116, 105307. [Google Scholar] [CrossRef] [PubMed]
  33. Kurskaya, O.; Prokopyeva, E.; Bi, H.; Sobolev, I.; Murashkina, T.; Shestopalov, A.; Wei, L.; Sharshov, K. Anti-Influenza Activity of Medicinal Material Extracts from Qinghai-Tibet Plateau. Viruses 2022, 14, 360. [Google Scholar] [CrossRef] [PubMed]
  34. Shen, M.; Liu, K.; Liang, Y.; Liu, G.; Sang, J.; Li, C. Extraction Optimization and Purification of Anthocyanins from Lycium Ruthenicum Murr. and Evaluation of Tyrosinase Inhibitory Activity of the Anthocyanins. J. Food Sci. 2020, 85, 696–706. [Google Scholar] [CrossRef] [PubMed]
  35. Yao, C.; Narumiya, S. Prostaglandin-Cytokine Crosstalk in Chronic Inflammation. Br. J. Pharmacol. 2019, 176, 337–354. [Google Scholar] [CrossRef]
  36. Lawrence, T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651. [Google Scholar] [CrossRef]
  37. Moskalev, A.; Guvatova, Z.; Lopes, I.D.A.; Beckett, C.W.; Kennedy, B.K.; De Magalhaes, J.P.; Makarov, A.A. Targeting Aging Mechanisms: Pharmacological Perspectives. Trends Endocrinol. Metab. 2022, 33, 266–280. [Google Scholar] [CrossRef]
  38. Campisi, J.; Kapahi, P.; Lithgow, G.J.; Melov, S.; Newman, J.C.; Verdin, E. From Discoveries in Ageing Research to Therapeutics for Healthy Ageing. Nature 2019, 571, 183–192. [Google Scholar] [CrossRef]
  39. Lin, Y.; Qi, X.; Liu, H.; Xue, K.; Xu, S.; Tian, Z. The Anti-Cancer Effects of Fucoidan: A Review of Both in Vivo and in Vitro Investigations. Cancer Cell Int. 2020, 20, 154. [Google Scholar] [CrossRef]
  40. Gao, H.-M.; Hong, J.-S. Why Neurodegenerative Diseases Are Progressive: Uncontrolled Inflammation Drives Disease Progression. Trends Immunol. 2008, 29, 357–365. [Google Scholar] [CrossRef]
  41. Hajialyani, M.; Hosein Farzaei, M.; Echeverría, J.; Nabavi, S.M.; Uriarte, E.; Sobarzo-Sánchez, E. Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence. Molecules 2019, 24, 648. [Google Scholar] [CrossRef]
  42. Liu, L.; Liu, J.; Bao, J.; Bai, Q.; Wang, G. Interaction of Microglia and Astrocytes in the Neurovascular Unit. Front. Immunol. 2020, 11, 1024. [Google Scholar] [CrossRef] [PubMed]
  43. Youdim, M.B.H.; Lavie, L. Selective MAO-A and B Inhibitors, Radical Scavengers and Nitric Oxide Synthase Inhibitors in Parkinson’s Desease. Life Sci. 1994, 55, 2077–2082. [Google Scholar] [CrossRef] [PubMed]
  44. Li, L.; Zhang, C.-W.; Chen, G.Y.J.; Zhu, B.; Chai, C.; Xu, Q.-H.; Tan, E.-K.; Zhu, Q.; Lim, K.-L.; Yao, S.Q. A Sensitive Two-Photon Probe to Selectively Detect Monoamine Oxidase B Activity in Parkinson’s Disease Models. Nat. Commun. 2014, 5, 3276. [Google Scholar] [CrossRef] [PubMed]
  45. Jovanović, A. Cardioprotective Signalling: Past, Present and Future. Eur. J. Pharmacol. 2018, 833, 314–319. [Google Scholar] [CrossRef]
  46. Zheng, Q.; Wang, H.; Hou, W.; Zhang, Y. Use of Anti-Angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study. Front. Cardiovasc. Med. 2021, 8, 755191. [Google Scholar] [CrossRef]
  47. Hou, C.-W.; Chen, I.-C.; Shu, F.-R.; Feng, C.-H.; Hung, C.-T. Protective Effect of Supplementation with Lycium Ruthenicum Murray Extract from Exhaustive Exercise-Induced Cardiac Injury in Rats. Chin. Med. J. 2019, 132, 1005–1006. [Google Scholar] [CrossRef]
  48. Smart, D. Radiation Toxicity in the Central Nervous System: Mechanisms and Strategies for Injury Reduction. Semin. Radiat. Oncol. 2017, 27, 332–339. [Google Scholar] [CrossRef]
  49. Brizel, D.M.; Wasserman, T.H.; Henke, M.; Strnad, V.; Rudat, V.; Monnier, A.; Eschwege, F.; Zhang, J.; Russell, L.; Oster, W.; et al. Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer. J. Clin. Oncol. 2000, 18, 3339–3345. [Google Scholar] [CrossRef]
  50. Kouvaris, J.R.; Kouloulias, V.E.; Vlahos, L.J. Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector. Oncologist 2007, 12, 738–747. [Google Scholar] [CrossRef]
  51. Ramesh, A.; Kumar, S.; Brouillard, A.; Nandi, D.; Kulkarni, A. A Nitric Oxide (NO) Nanoreporter for Noninvasive Real-Time Imaging of Macrophage Immunotherapy. Adv. Mater. 2020, 32, 2000648. [Google Scholar] [CrossRef] [PubMed]
  52. Theivendran, S.; Gu, Z.; Tang, J.; Yang, Y.; Song, H.; Yang, Y.; Zhang, M.; Cheng, D.; Yu, C. Nanostructured Organosilica Nitric Oxide Donors Intrinsically Regulate Macrophage Polarization with Antitumor Effect. ACS Nano 2022, 16, 10943–10957. [Google Scholar] [CrossRef] [PubMed]
  53. Mills, C.D.; Lenz, L.L.; Harris, R.A. A Breakthrough: Macrophage-Directed Cancer Immunotherapy. Cancer Res. 2016, 76, 513–516. [Google Scholar] [CrossRef] [PubMed]
  54. Zhang, X.; Jing, S.; Lin, H.; Sun, W.; Jiang, W.; Yu, C.; Sun, J.; Wang, C.; Chen, J.; Li, H. Anti-Fatigue Effect of Anwulignan via the NRF2 and PGC-1α Signaling Pathway in Mice. Food Funct. 2019, 10, 7755–7766. [Google Scholar] [CrossRef] [PubMed]
  55. Payab, M.; Hasani-Ranjbar, S.; Baeeri, M.; Rahimifard, M.; Arjmand, B.; Haghi-Aminjan, H.; Abdollahi, M.; Larijani, B. Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes. Iran. Biomed. J. 2020, 24, 155–163. [Google Scholar] [CrossRef] [PubMed]
  56. Zhang, W.-L.; Zhu, L.; Jiang, J.-G. Active Ingredients from Natural Botanicals in the Treatment of Obesity. Obes. Rev. 2014, 15, 957–967. [Google Scholar] [CrossRef] [PubMed]
  57. Wadden, T.A.; Berkowitz, R.I.; Womble, L.G.; Sarwer, D.B.; Phelan, S.; Cato, R.K.; Hesson, L.A.; Osei, S.Y.; Kaplan, R.; Stunkard, A.J. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N. Engl. J. Med. 2005, 353, 2111–2120. [Google Scholar] [CrossRef]
  58. Fu, C.; Jiang, Y.; Guo, J.; Su, Z. Natural Products with Anti-Obesity Effects and Different Mechanisms of Action. J. Agric. Food Chem. 2016, 64, 9571–9585. [Google Scholar] [CrossRef]
  59. Lee, H.S.; Heo, C.U.; Song, Y.-H.; Lee, K.; Choi, C.-I. Naringin Promotes Fat Browning Mediated by UCP1 Activation via the AMPK Signaling Pathway in 3T3-L1 Adipocytes. Arch. Pharm. Res. 2023, 46, 192–205. [Google Scholar] [CrossRef]
  60. Wang, X.; Ai, X.; Zhu, Z.; Zhang, M.; Pan, F.; Yang, Z.; Wang, O.; Zhao, L.; Zhao, L. Pancreatic Lipase Inhibitory Effects of Peptides Derived from Sesame Proteins: In Silico and in Vitro Analyses. Int. J. Biol. Macromol. 2022, 222, 1531–1537. [Google Scholar] [CrossRef]
  61. Li, B.; Zhou, B.; Lu, H.; Ma, L.; Peng, A.-Y. Phosphaisocoumarins as a New Class of Potent Inhibitors for Pancreatic Cholesterol Esterase. Eur. J. Med. Chem. 2010, 45, 1955–1963. [Google Scholar] [CrossRef] [PubMed]
  62. Gaitonde, D.Y.; Moore, F.C.; Morgan, M.K. Influenza: Diagnosis and Treatment. Am. Fam. Physician 2019, 100, 751–758. [Google Scholar] [PubMed]
  63. Rajendran, P.; Nandakumar, N.; Rengarajan, T.; Palaniswami, R.; Gnanadhas, E.N.; Lakshminarasaiah, U.; Gopas, J.; Nishigaki, I. Antioxidants and Human Diseases. Clin. Chim. Acta 2014, 436, 332–347. [Google Scholar] [CrossRef] [PubMed]
  64. Lee, Y.-M.; Yoon, Y.; Yoon, H.; Park, H.-M.; Song, S.; Yeum, K.-J. Dietary Anthocyanins against Obesity and Inflammation. Nutrients 2017, 9, 1089. [Google Scholar] [CrossRef] [PubMed]
  65. Liu, Z.; Dang, J.; Wang, Q.; Yu, M.; Jiang, L.; Mei, L.; Shao, Y.; Tao, Y. Optimization of Polysaccharides from Lycium Ruthenicum Fruit Using RSM and Its Anti-Oxidant Activity. Int. J. Biol. Macromol. 2013, 61, 127–134. [Google Scholar] [CrossRef] [PubMed]
  66. Wang, Y.; Luan, G.; Zhou, W.; Meng, J.; Wang, H.; Hu, N.; Suo, Y. Subcritical Water Extraction, UPLC-Triple-TOF/MS Analysis and Antioxidant Activity of Anthocyanins from Lycium Ruthenicum Murr. Food Chem. 2018, 249, 119–126. [Google Scholar] [CrossRef]
  67. Liu, Z.; Tang, X.; Liu, C.; Dong, B.; Shao, Y.; Liu, B.; Yue, H. Ultrasonic Extraction of Anthocyanins from Lycium Ruthenicum Murr. and Its Antioxidant Activity. Food Sci. Nutr. 2020, 8, 2642–2651. [Google Scholar] [CrossRef]
  68. Gao, Q.; Song, Y.; Liang, Y.; Li, Y.; Chang, Y.; Ma, R.; Cao, X.; Wang, S. Dynamics of Physicochemical Properties, Functional Compounds and Antioxidant Capacity during Spontaneous Fermentation of Lycium Ruthenicum Murr. (Qinghai-Tibet Plateau) Natural Vinegar. Foods 2022, 11, 1344. [Google Scholar] [CrossRef]
  69. Song, J.-L.; Gao, Y.; Xu, J. Protective Effects of Methanolic Extract Form Fruits of Lycium Ruthenicum Murr on 2,2′-Azobis (2-Amidinopropane) Dihydrochloride-Induced Oxidative Stress in LLC-PK1 Cells. Pharmacogn. Mag. 2014, 10, 522–528. [Google Scholar]
  70. Wu, T.; Lv, H.; Wang, F.; Wang, Y. Characterization of Polyphenols from Lycium Ruthenicum Fruit by UPLC-Q-TOF/MSE and Their Antioxidant Activity in Caco-2 Cells. J. Agric. Food Chem. 2016, 64, 2280–2288. [Google Scholar] [CrossRef]
Figure 1. Chemical structure of the main bioactive components in LRM. Anthocyanins: malvidin (A), pelargonidin (B), peonidin 3-O-[6-O-(4-O-E-p-coumaroyl-O-α-rhamnopyranosyl)-β-glucopyranoside]-5-O-β-glucopyranoside (C); phytosterol: stigmasterol (D); carotenoids: β-carotene (E), neoxanthin (F); alkaloid: lyrium spermidine A (G); fatty acid: linoleic acid (H); phenolic acids: caffeic acid (I), vanillic acid (J).
Figure 1. Chemical structure of the main bioactive components in LRM. Anthocyanins: malvidin (A), pelargonidin (B), peonidin 3-O-[6-O-(4-O-E-p-coumaroyl-O-α-rhamnopyranosyl)-β-glucopyranoside]-5-O-β-glucopyranoside (C); phytosterol: stigmasterol (D); carotenoids: β-carotene (E), neoxanthin (F); alkaloid: lyrium spermidine A (G); fatty acid: linoleic acid (H); phenolic acids: caffeic acid (I), vanillic acid (J).
Nutrients 15 04181 g001
Figure 2. Chemical structure of polyphenolic glycosides isolated from LRM with neuroprotective effects [32]. Compound 1: lyciumserin A (7-hydroxycoumarin-3-O-[6-O-(4-O-p-trans-coumaroyl)-α-L-rhamnopyranosyl]-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (A), compound 2: lyciumserin B (7-hydroxycoumarin-3-O-[6-O-(4-O-(4-O-β-d-glucopyranosyl)-trans-p-coumaroyl)-α-L-rhamnopyranosyl]-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (B), compound 3: lyciumserin C (7-hydroxycoumarin-3-O-(6-O-α-L-rhamnopyranosyl)-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (C), compound 5: lyciumserin E (6-O-(3-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyrano-side) (R: β-OH) and compound 6: lyciumserin F (6-O-(3-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranoside) (R: α-OH) (D), compound 11: puchikrin (E), compound 16: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranosyl-methanol (R: α-OCH3), compound 17: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyranoside (R: β-OH), and compound 18: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranoside (R: α-OH) (F).
Figure 2. Chemical structure of polyphenolic glycosides isolated from LRM with neuroprotective effects [32]. Compound 1: lyciumserin A (7-hydroxycoumarin-3-O-[6-O-(4-O-p-trans-coumaroyl)-α-L-rhamnopyranosyl]-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (A), compound 2: lyciumserin B (7-hydroxycoumarin-3-O-[6-O-(4-O-(4-O-β-d-glucopyranosyl)-trans-p-coumaroyl)-α-L-rhamnopyranosyl]-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (B), compound 3: lyciumserin C (7-hydroxycoumarin-3-O-(6-O-α-L-rhamnopyranosyl)-β-D-glucopyranosyl-5-O-β-D-glucopyranoside) (C), compound 5: lyciumserin E (6-O-(3-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyrano-side) (R: β-OH) and compound 6: lyciumserin F (6-O-(3-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranoside) (R: α-OH) (D), compound 11: puchikrin (E), compound 16: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranosyl-methanol (R: α-OCH3), compound 17: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyranoside (R: β-OH), and compound 18: 6-O-(4-O-p-trans-coumaroyl-α-L-rhamnopyranosyl)-α-D-glucopyranoside (R: α-OH) (F).
Nutrients 15 04181 g002
Table 1. Nutritional information of Lycium ruthenicum Murray (LRM) fruits.
Table 1. Nutritional information of Lycium ruthenicum Murray (LRM) fruits.
Nutrientsg/100 g DWNutrientsmg/100 g DW
Total carbohydrates67.0 ± 1.2Vitamins12.42 ± 1.26
Dietary fiber12.1 ± 0.1Macroelements22.1 ± 1.6
Proteins11.5 ± 0.3Microelements129.2 ± 9.1 *
Ash6.3 ± 0.1Carotenoids1.52 ± 0.01
Fat3.0 ± 0.1Anthocyanins25.1 ± 1.3
Organic acids4.69 ± 0.13Polysaccharides31.3 ± 1.6
* = μg/g DW.
Table 2. Summary of pharmacological studies for Lycium ruthenicum Murray (LRM).
Table 2. Summary of pharmacological studies for Lycium ruthenicum Murray (LRM).
Pharmacological
Activity
Tested SubstanceStudy ModelDose/ConcentrationStudy Result(s)Ref.
Anti-inflammationAnthocyaninSprague Dawley rats100 mg/kgDecreased: TNF-α and IL-6
Increased: IL-10
[13]
AnthocyaninNeuro-2a cells and Male C57BL/6 mice10 μM (in vitro) and 50 and 100 mg/kg (in vivo)(in vitro)
Decreased: COX-2, TNF-α, IL-6, IL-1β, and p-NF-κBp65
(in vivo)
Decreased: p-NF-κB, TNF-α, IL-1β, and IL-6
[14]
Fruit extractKunming mice0.05, 0.1, 0.2, and 0.5 mg/gDecreased: TNF-α, IL-1β, IL-2, and IL-6[15]
Fruit extractMale ApoE−/− mice140 mg/kgDecreased: Tnf-α (compared with NC and WD)
Not significantly changed: Il-6 (compared with NC and WD) and Il-10 (compared with WD)
Increased: Il-4 (compared with WD)
[16]
AnthocyaninFemale Sprague Dawley rats50, 100, and 200 mg/kgDecreased: NF-κB, IL-1β, COX-2, and TNF-α[17]
Anti-agingAnthocyaninSprague Dawley rats100 mg/kgDecreased: serum aging markers (AGEs and MDA)
Increased: swimming speed
Improved: amino acid metabolic disturbance
[13]
AnthocyaninMale C57BL/6 mice50 and 100 mg/kgImproved: cognitive impairment (enhanced spatial learning and memory abilities)[14]
Fruit extractC. elegans2, 5, and 10 mg/mLDecreased: mortality rate (for heat shock), motility, lipofuscin (age pigment), reproductive ability, and age-related gene expression (age-1)
Increased: average lifespan, SOD, CAT, oxidative resistance, irradiation tolerance, pump rate, and age-related gene expression (daf-16, sod-2, sod-3, hsp-16.2, sir-2.1, daf-12, jnk-1)
Improved: nuclear localization of DAF-16
[18]
AnticancerFruit extractHuman breast cancer cells2, 4, and 6 mg/mLAntiproliferative activity, EC50 of free extract: 4.08 ± 0.09 mg/mL
Activated: p53, p21, CDK4, Cyclin E, Bax, and Caspase3 (p53 signaling pathway)
[19]
PolysaccharideAsPC-1, BxPC-3, and PANC-1 cells and BALB/cA nu/nu mice7.45 and 14.9 μM (in vitro) and 0.5 and 40 mg/kg (in vivo)(in vitro)
Decreased: proliferation of pancreatic cancer cells
(in vivo)
Decreased: tumor sizes, tumor weights, Ki67, CD31, total NF-κB, p-GSK-3β, β-Catenin, p-P38, Bcl-2, caspase-3, and caspase-9
Increased: apoptosis
[20]
PolysaccharideAsPC-1, BxPC-3, and PANC-1 cells4.36 and 8.71 μMDecreased: proliferation of pancreatic cancer cells, invasion ability, p-AKT, p-GSK-3β, p-FAK, and p-p38[21]
Polysaccharide and anthocyaninLoVo cells and HepG2 cellsPolysaccharide 150, 300, and 500 μg/mL (with anthocyanin 20 μg/mL)Decreased: proliferation of carcinoma cells
Inhibited: replication by G0–G1 arrest
Increased: apoptosis
[22]
HepatoprotectiveAnthocyaninSprague Dawley rats100 mg/kgImproved: histological damages
Decreased: serum AST, ALT, and LDH levels and Fas/FasL mRNA expression level (relieved liver cell death)
[13]
Fruit extractMale ApoE−/− mice140 mg/kgSimilar: liver morphology, weight, indices of liver/body weight, total bile acid level, serum ALT level, TC, TG, LDL, and HDL-c levels (compared to WD)
Decreased: AST levels (compared to NC) and size of fat droplet in liver (compared to WD)
[16]
NeuroprotectiveAnthocyaninNeuro-2a cells and Male C57BL/6 mice10 μM (in vitro) and 50 and 100 mg/kg (in vivo)(in vitro)
Decreased: COX-2, TNF-α, IL-6, IL-1β, and p-NF-κBp65
Increased: cell viability of CML-treated cells
Improved: CML-induced apoptosis
(in vivo)
Decreased: p-NF-κB, TNF-α, IL-1β, IL-6, and caspase-3 (relieved hippocampus neuronal apoptosis)
Improved: cognitive impairment (enhanced spatial learning and memory abilities)
[14]
AnthocyaninFemale Sprague Dawley rats50, 100, and 200 mg/kgDecreased: d-gal-Induced neuronal apoptosis, p-JNK, Bax/Bcl-2 ratio, caspase-3, RAGE, BACE-1, Aβ42, GFAP, and Iba-1
Improved: learning, memory impairment, memory ability, and passive avoidance
[17]
PolysaccharidePrimary cortical neuronal cells in Sprague Dawley rats0, 5, 10, and 20 μMIncreased: cell viability and expression levels of Nrf2
Inhibited: apoptosis (decreased caspase-3 activity and ratio of bax/bcl-2)
[23]
Polyphenolic GlycosidesPC12 cells25, 50, and 100 μMMAO-B inhibition rates (compounds 1, 2, 11, 16, and 17/1): IC50 value of 60.7 ± 1.7, 22.2 ± 0.8, 79.3 ± 2.4, 68.9 ± 1.5, and 75.5 ± 3.8 μM, respectively
Decreased: apoptosis (compounds 1, 2, and 6)
Improved: cell viabilities (compounds 13 and 5/6), morphologic changes (compounds 1 and 2)
[24]
CardioprotectiveFruit extractICR mice375 and 750 mg/kgDecreased: CK-MB and LDH activities (amelioration of the myocardial histopathology), fibers necrosis, the number of inflammatory cells, and myocardial tissue (improved myocardial tissue damage)[25]
Radiation injury protectiveFruit extractMale Kunming mice2, 4, and 6 g/kgDecreased: caspase-3, P53, and apoptosis
Increased: thymus index, spleen index, and DNA content
[26]
ImmunomodulationFruit extractMale Kunming mice2, 4, and 6 g/kgIncreased: thymus index and spleen index[26]
PolysaccharideRAW264.7 cells25, 50, 100, 200, 500, and 1000 μg/mLNot significantly changed: cell viability at concentrations of less than 200 μg/mL
Increased: NO release (25, 50, 100, and 200 μg/mL; activation of macrophage)
[27]
PolysaccharideFemale Kunming mice25, 50, and 100 mg/kgIncreased: thymus index, spleen index, T cell and B cell proliferation, macrophage phagocytosis, serum hemolysin formation, IL-2, IL-6, and TNF-α (immunosuppressed mice)[28]
AnthocyaninSynovial fibroblasts (Isolation from RA patients)100, 200, and 400 μg/mLDecreased: SF cell viability, proliferation
Not significantly changed: T cells and monocyte/macrophage development
[29]
Anti-fatigueFruit extractKunming mice0.05, 0.1, 0.2, and 0.5 mg/gExercise-induced oxidative stress and inflammation were reduced.
Decreased: LDH, TNF-α, IL-1β, IL-2, and IL-6 level
Increased: SOD level
[15]
PolysaccharideMale BALB/c mice50, 100, and 200 mg/kgDecreased: immobility times, BUN, TG, CPK, LDH, and MDA levels
Increased: glucose, SOD, and GPx levels
LRM helped mobilize TG during exercise and protected microparticles by preventing lipid oxidation by modifying several enzyme activities.
[30]
Anti-obesity and antidiabeticFruit extractMale ApoE−/− mice140 mg/kgDecreased: Pparγ and Fasn (compared to NC) and Srebp1 (compared to WD)
Not significantly changed: Scd, Lpl, and Lxrα
Increased: Cpt (compared to WD)
[16]
Seed oilCell free0.80, 1.60, 3.20, 6.40, and 12.80 mg/mLPancreatic lipase inhibitory activity: IC50 value of 12.4 ± 0.1 mg/mL
CEase inhibitory activity: IC50 value of 2.6 ± 0.1 mg/mL (reversible non-competitive inhibition)
[31]
Phenylpropanoid derivativesCell free400 μM
(Compound 13: 100, 200, 400, and 800 μM)
Most of the compounds showed weak inhibitory activity.
Compound 13 showed an effect similar to that of the positive control (acarbose) and increased the inhibitory effect in a dose-dependent manner.
[32]
Anti-influenzaFruit extractMDCK cell and influenza virus A/H3N215.625, 31.25, 62.5, 125, 250, and 500 μg/mLDecreased: influenza activity (CC50 value was higher than 125 μg/mL)
Increased: MDCK cell viability infected with the virus
[33]
Tyrosinase inhibitoryFruit extract and purified anthocyaninCell free0, 0.75, 1.5, 2.25, and 3 mg/mLTyrosinase monophenolase inhibitory activity: IC50 value of 3.0 ± 0.02 mg/mL (extract) and 1.5 ± 0.058 mg/mL (purified), reversible competitive inhibition, and Ki = 39.8 ± 1.4 mg/mL
Diphenolase inhibitory activity: 3 mg/mL, 30.8 ± 1.0% (extract) and 3 mg/mL, 42.2 ± 0.77% (purified), reversible uncompetitive inhibition, and Kis = 2.4 ± 0.10 mg/mL
[34]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, H.S.; Choi, C.-I. Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity. Nutrients 2023, 15, 4181. https://doi.org/10.3390/nu15194181

AMA Style

Lee HS, Choi C-I. Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity. Nutrients. 2023; 15(19):4181. https://doi.org/10.3390/nu15194181

Chicago/Turabian Style

Lee, Ho Seon, and Chang-Ik Choi. 2023. "Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity" Nutrients 15, no. 19: 4181. https://doi.org/10.3390/nu15194181

APA Style

Lee, H. S., & Choi, C. -I. (2023). Black Goji Berry (Lycium ruthenicum Murray): A Review of Its Pharmacological Activity. Nutrients, 15(19), 4181. https://doi.org/10.3390/nu15194181

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop